1.01
Schlusskurs vom Vortag:
$1.01
Offen:
$1.02
24-Stunden-Volumen:
291.96K
Relative Volume:
0.15
Marktkapitalisierung:
$13.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.70M
KGV:
-0.9182
EPS:
-1.1
Netto-Cashflow:
$-8.57M
1W Leistung:
-6.94%
1M Leistung:
+5.28%
6M Leistung:
-2.43%
1J Leistung:
-62.92%
Marker Therapeutics Inc Stock (MRKR) Company Profile
Firmenname
Marker Therapeutics Inc
Sektor
Branche
Telefon
(713) 400-6400
Adresse
2450 HOLCOMBE BLVD, HOUSTON, TX
Vergleichen Sie MRKR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRKR
Marker Therapeutics Inc
|
1.01 | 13.07M | 0 | -9.70M | -8.57M | -1.10 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.47 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.58 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-05 | Eingeleitet | Canaccord Genuity | Buy |
2021-03-25 | Eingeleitet | Piper Sandler | Overweight |
2021-03-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
2019-05-30 | Eingeleitet | ROTH Capital | Buy |
2019-03-01 | Eingeleitet | Janney | Buy |
2018-12-03 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Marker Therapeutics Inc Aktie (MRKR) Neueste Nachrichten
Is this a good reentry point in Marker Therapeutics Inc.Market Trend Report & AI Driven Price Forecasts - newser.com
Developing predictive dashboards with Marker Therapeutics Inc. dataDip Buying & Reliable Entry Point Alerts - newser.com
Using R and stats models for Marker Therapeutics Inc. forecastingEarnings Recap Summary & Reliable Entry Point Trade Alerts - newser.com
Does Marker Therapeutics Inc. show high probability of reboundTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Tools to assess Marker Therapeutics Inc.’s risk profilePortfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
What valuation multiples suggest for Marker Therapeutics Inc. stockPortfolio Update Report & Advanced Swing Trade Entry Alerts - newser.com
Marker Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Volatility clustering patterns for Marker Therapeutics Inc.Dip Buying & Fast Gain Stock Tips - newser.com
Why retail investors pile into Marker Therapeutics Inc. stock2025 Top Gainers & High Win Rate Trade Tips - newser.com
Marker Therapeutics Inc. stock daily chart insightsAnalyst Downgrade & Entry Point Confirmation Signals - newser.com
Real time breakdown of Marker Therapeutics Inc. stock performanceJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Best data tools to analyze Marker Therapeutics Inc. stock2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
What makes Marker Therapeutics Inc. (GX1) stock appealing to growth investorsJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - Sahm
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment - TipRanks
Marker Therapeutics Launches Phase 1 RAPID Trial for Multi-Antigen Recognizing T Cells as Off-the-Shelf Treatment for AML and MDS - Quiver Quantitative
100x10^6‑cell initial dose: Marker Therapeutics treats first patient with MT‑401 in Phase 1 OTS RAPID study - Stock Titan
Marker Therapeutics Inc GX1 Stock Analysis and ForecastSwing Trading Watchlist & Exceptional Capital Trading - earlytimes.in
Is Marker Therapeutics Inc. trending in predictive chart models2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Will Marker Therapeutics Inc. stock maintain momentum in 2025Quarterly Portfolio Summary & Daily Entry Point Alerts - newser.com
How forex fluctuations impact Marker Therapeutics Inc. (GX1) stockMarket Risk Report & AI Enhanced Execution Alerts - newser.com
Will Marker Therapeutics Inc. (GX1) stock split increase liquidity2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Is Marker Therapeutics Inc. (GX1) stock worth holding before Fed meeting2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Is Marker Therapeutics Inc. (GX1) stock prepared for digital transition2025 Short Interest & Real-Time Volume Trigger Notifications - newser.com
Visualizing Marker Therapeutics Inc. stock with heatmapsJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
Finanzdaten der Marker Therapeutics Inc-Aktie (MRKR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Marker Therapeutics Inc-Aktie (MRKR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):